Besremi (ropeginterferon alfa-2b-njft) for Essential thrombocythemia
What the FDA decided
The FDA approved PharmaEssentia's sBLA for Besremi (ropeginterferon alfa-2b-njft) in Essential thrombocythemia. Label expansion into essential thrombocythemia, the first new FDA-approved ET treatment in nearly 30 years (PharmaEssentia release, August 31, 2026). Approved for adults regardless of genotype, including newly diagnosed patients. In the Phase 3 SURPASS ET trial against anagrelide, 37.4% of Besremi patients had a durable response at months 9 and 12 versus 3.6% on anagrelide.
Who this decision matters to
Essential Thrombocythemia is a myeloproliferative neoplasm characterized by overproduction of platelets by bone marrow, resulting in very high platelet counts. Patients are at increased risk for blood clots and, paradoxically, bleeding complications. Many cases involve mutations in JAK2, CALR, or MPL genes.
Prevalence: Approximately 1-2 cases per 100,000 people; median age of diagnosis is 60 years. See our full Essential Thrombocythemia page for current treatments, recruiting trials, and community resources.
Where Essential Thrombocythemia treatment stands today
Read our full Essential Thrombocythemia treatment summary
Research in Essential Thrombocythemia is evolving toward personalized treatment strategies that account for your specific genetic makeup and risk profile. Clinical trials are testing targeted JAK inhibitors, HDAC inhibitors, and innovative agents designed to reduce platelet production while preserving quality of life and keeping side effects manageable.
Understanding your mutation status, genetic risk, and individual clot and bleeding risk allows your hematologist to tailor therapy specifically to your situation. Hydroxyurea has long been standard treatment for platelet reduction, but emerging agents offer alternatives that may work better for some patients with fewer side effects.
Discussing trial opportunities with your hematologist is an important part of developing a comprehensive treatment plan suited to your needs.
The Essential Thrombocythemia page has every treatment and trial →Meanwhile, 38 Essential Thrombocythemia trials are recruiting
Whatever the FDA decides here, research on Essential Thrombocythemia does not stop. A few currently enrolling studies, US sites first:
You'll hear about future FDA decisions and new recruiting trials for Essential Thrombocythemia. Unsubscribe anytime.
Frequently asked questions
Has the FDA decided on Besremi?
The FDA has already decided. It approved the application.
Details: the outcome and what it means are at the top of this page.
Source: FDA approval notice
What was Besremi approved for?
The FDA approved PharmaEssentia's sBLA for Besremi in Essential thrombocythemia.
What to know: Label expansion into essential thrombocythemia, the first new FDA-approved ET treatment in nearly 30 years (PharmaEssentia release, August 31, 2026). Approved for adults regardless of genotype, including newly diagnosed patients. In the Phase 3 SURPASS ET trial against anagrelide, 37.4% of Besremi patients had a durable response at months 9 and 12 versus 3.6% on anagrelide.
Is there already an FDA-approved treatment for Essential Thrombocythemia?
Trial Friend's drug list has no FDA-approved drug for Essential Thrombocythemia yet.
Check: the Essential Thrombocythemia page also searches FDA drug labels for approved treatments.
How much will Besremi cost?
Trial Friend does not list a price for Besremi. What you pay depends on your insurance and on help from the drugmaker or a charity fund.
Help paying: drugmaker programs and charity funds usually open at launch.
Find help: the patient assistance finder lists programs by insurance type.
What happens after the Besremi decision?
This page updates with the outcome the day it is announced.
If approved: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.
If not approved: a complete response letter means the FDA declined the application in its current form. Many are about manufacturing or how data were presented, and companies often resubmit.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from FDA approval notice. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.